For example, while the basic compound for AbbVie's best-selling anti-inflammatory drug Humira expires in December, AbbVie CEO Richard Gonzalez assured analysts in 2015 that its nearly 70 additional patents would keep the drug competition-free until 2022. "Any company seeking to market a biosimilar version of Humira will have to contend with this extensive patent estate which AbbVie intends to enforce vigorously," he said. Between 2010 and January 2016, AbbVie increased the wholesale price of Humira by 138%, according to Truven Health Analytics. Two doses cost $1,600 in 2010; now they're $3,800. Since 2005, AbbVie has made more than $53 billion from sales of Humira, according to IMS Health. By 2020, the company expects the drug to deliver $18 billion per year.